The Heparanase Inhibitor (Sulodexide) Decreases Urine Glycosaminoglycan Excretion and Mitigates Functional and Histological Renal Damages in Diabetic Rats

1. Zemin C, EC. M. Pathogenesis of diabetic nephropathy. J Diabetes Invest 2011;2:243-7.10.1111/j.2040-1124.2011.00131.x401496024843491Search in Google Scholar

2. Fard AA, Abbasnezhad P, Makhdomi K, et al. Association of Serum Prolactin Concentrations with Renal Failure in Diabetic Patients. Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2017;24(3):179-85.10.1515/rjdnmd-2017-0023Search in Google Scholar

3. Ibrahim HN, TH. H. Diabetic nephropathy. J Am Soc Nephrol. 1997;8:487-93.10.1681/ASN.V834879071718Search in Google Scholar

4. Atkins R, Zimmet PI-I. World Kidney Day Steering Committee: Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol. 2010;6:134-6.10.1038/nrneph.2010.1020186229Search in Google Scholar

5. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271(17):10079-86.10.1074/jbc.271.17.100798626565Search in Google Scholar

6. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nature medicine. 1998;4(6):691-7.10.1038/nm0698-6919623978Search in Google Scholar

7. Makino H, Ikeda S, Haramoto T, Ota Z. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Nephron. 1992;61(4):415-21.10.1159/0001869591501738Search in Google Scholar

8. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proceedings of the National Academy of Sciences. 1979;76(3):1303-7.10.1073/pnas.76.3.1303383239155819Search in Google Scholar

9. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PloS one. 2011;6(2):e17312.10.1371/journal.pone.0017312304309821364956Search in Google Scholar

10. Rops AL, Van den Hoven MJ, Veldman BA, et al. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrology Dialysis Transplantation. 2012;27(7):2853-61.10.1093/ndt/gfr73222187315Search in Google Scholar

11. Rosenzweig L, Kanwar Y. Removal of sulfated (heparan sul-fate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest. 1982;47(2):177-84.Search in Google Scholar

12. Kolset S, Reinholt F, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60(12):976-86.10.1369/0022155412465073Search in Google Scholar

13. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovascular Therapeutics. 2006;24(3-4):214-26.10.1111/j.1527-3466.2006.00214.xSearch in Google Scholar

14. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide. Med Res Rev. 1998;18(1):1-20.10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4Search in Google Scholar

15. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1997;12(11):2295-300.10.1093/ndt/12.11.2295Search in Google Scholar

16. Skrha J, Perusicová J, Pont’uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25-31.10.1016/S0168-8227(97)00076-4Search in Google Scholar

17. Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kid Dis,2011;58(5):729-36.10.1053/j.ajkd.2011.06.020Search in Google Scholar

18. Reddi AS, Ramamurti R, Miller M, et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol. 1991;45(119-131).10.1016/0885-4505(91)90014-CSearch in Google Scholar

19. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes. 2007;56(7):1825-33.10.2337/db06-1226Search in Google Scholar

20. Brosius FC, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-12.10.1681/ASN.2009070721Search in Google Scholar

21. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev. 2001;17(6):412-21.10.1002/dmrr.236Search in Google Scholar

22. Vanden Born J, Van Kraats AA, Hill S, et al. Vessel wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in the rat. Nephrol Dial Transplant. 1997;12(2):27-31.Search in Google Scholar

23. De Lima CR, Aguiar JA, Michelacci YM. Reduced urinary excretion of sulfated polysaccharides in diabetic rats. Biochim Biophys Acta.2005;1741(1-2):30-41.10.1016/j.bbadis.2004.10.001Search in Google Scholar

24. Cadaval RA, Kohlman O, Michelacci YM. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology. 2000;10(2):185-92.10.1093/glycob/10.2.185Search in Google Scholar

25. Yavuz DG, Ersöz HO, Tuncel M et al. Effects of Aminoguanidine on Glomerular Basement Membrane Thickness and Anionic Charge in a Diabetic Rat Model. Int Jnl Experimental Diab Res. 2001;2:225-32.10.1155/EDR.2001.225Search in Google Scholar

26. McAuliffe A, Fisher E, McLennan S, et al. Urinary glycosaminoglycan excretion in NIDDM subjects: Its relationship to albuminura. Diabetic medicine. 1996;13(8):758-63.10.1002/(SICI)1096-9136(199608)13:8<758::AID-DIA160>3.0.CO;2-TSearch in Google Scholar

27. Popławska-Kita A, Mierzejewska-Iwanowska B, Szelachowska M et al. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression. Diabetes Metab Res Rev 2008;24(4):310-7.10.1002/dmrr.808Search in Google Scholar

28. Cechowska-Pasko M, Pałka J, Bańkowski E. Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Mol Cell biochem. 1996;154(1):1-8.10.1007/BF00248454Search in Google Scholar

29. Juretić D, Krajnović V, Lukac-Bajalo J. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta diabetol. 2002;39(3):123-8.10.1007/s005920200030Search in Google Scholar

30. Harvey SJ, Miner JH. Breaking down the barrier: evidence against a role for heparan sulfate in glomerular permselectivity. J Am Soc Nephrology. 2007.10.1681/ASN.2007010086Search in Google Scholar